Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given written consent to take part in the study.
- People who have been diagnosed with advanced clear cell or papillary renal cell carcinoma (a type of kidney cancer), confirmed by a tissue sample, where no standard treatment is available, suitable, or the person has chosen not to have standard treatment.
- People taking part in the expansion phase of the study must have disease that can be measured on scans according to standard criteria.
- People whose general health and ability to carry out daily activities falls within an acceptable range (confirm with trial site for specific level required).
- People aged 18 or older.
- People expected to live for at least 3 months.
- People whose blood counts (white blood cells, platelets, and haemoglobin/red blood cell levels) meet the required levels, based on recent blood tests.
- People whose liver function blood test results fall within acceptable ranges.
- People who are already on regular ongoing kidney dialysis (haemodialysis) for at least the past three months.
- People whose kidney specialist and cancer doctor both agree that any further loss of kidney function from this treatment would not significantly affect their ongoing dialysis care.
- People who are able and willing to use two highly effective forms of contraception during treatment and for at least 3 months after the last dose (for males) or 6 months after the last dose (for females).
- Women who could become pregnant must have a negative pregnancy blood test before starting the study.
- People who are willing and able to attend all scheduled visits, treatments, tests, and other study requirements, including any travel involved.
Who may not be able to join:
- People who have been diagnosed with another cancer within the past 2 years, with some exceptions such as certain treated skin cancers, early-stage breast or cervical cancer, or low-grade prostate cancer being monitored without active treatment.
- People who have had radiotherapy within 2 weeks before the first dose.
- People who have received immunotherapy for cancer within the past 6 months.
- People who have received any other systemic (whole-body) cancer treatment within 2 weeks before the first dose.
- People who have not sufficiently recovered from side effects of previous cancer treatments.
- People who have taken part in another clinical trial or received an experimental treatment within 4 weeks before the first dose.
- People who are pregnant or breastfeeding.
- People with uncontrolled medical conditions, active infections, or mental health or social circumstances that could affect their ability to safely take part in the trial, as assessed by the trial team.
- People whose heart electrical activity (measured by a specific interval on an ECG) is above a certain level at the start of the study (confirm with trial site for details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +46702679544
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events and laboratory abnormalities as graded by NCI CTCAE v5.0.; Changes in arterial blood pressure measurements; Changes in pulse rate measurements; Changes in respiratory rate measurements; Changes in temperature measurements; Changes in physical examination findings; Maximum tolerable dose of orellanine
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.